ES · antibody-drug conjugate · biotechnology · oncology
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · Jun 2026 · $87M
Columbus Venture Partners lead, Mérieux Equity Partners lead, Bpifrance, COFIDES, Alta Life Sciences, Asabys Partners, CDTI through SICC Innvierte, FundPlus NV, Korys, Ysios Capital
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.